HUTCHMED (00013) has announced that the latest and updated data from several studies of its self-developed compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, in Chicago, USA.

Results from the pivotal Phase II registration study in China of savolitinib for the treatment of patients with gastric or gastroesophageal junction adenocarcinoma harboring MET amplification will be featured in a rapid oral abstract session. The study met its primary endpoint of objective response rate (ORR) as assessed by an Independent Review Committee (IRC) per RECIST 1.1 criteria. As of the data cutoff date of October 8, 2025, the IRC-assessed ORR was 32.3% (95% CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included an IRC-assessed disease control rate (DCR) of 63.1%, a median time to response (TTR) of 1.4 months, a median duration of response (DoR) of 9.7 months (95% CI: 3.7, 18.5), and a median progression-free survival (PFS) of 4.0 months (95% CI: 2.6, 5.0). These data supported the submission of a New Drug Application to China's National Medical Products Administration, which was accepted and granted priority review in December 2025.

Furthermore, additional analyses from the FRESCO, FRESCO-2, FRUSICA-1, and FRUSICA-2 studies of fruquintinib, along with results from investigator-initiated trials of fruquintinib and surufatinib in multiple potential oncology indications, will also be presented at the conference.